

## Conference Programme

Day 1 - 21 March 2023

08:15-09:00 **Welcome Coffee & Registrations**

09:00-09:05



### Conference Opening & Welcome Address Day 1

Sandrine Claus

*President, Pharmabiotic Research Institute*

09:05-10:20



### Fundamental Science Session

Chaired by Bruno Pot



09:05-09:30



### The Tumor Mycobiome

Ravid Straussman

*Principal Investigator, Weizmann Institute of Science*

09:30-09:55



### Lung Microbiome-based Diagnosis and Therapeutic in Chronic Pulmonary Disease

Genevieve Hery-Arnaud

*Professor of Bacteriology, University of Brest*

09:55-10:20



### The Role of Gut Microbiota in Cancer Immunotherapy

Carolina Alves Costa Silva

*PhD Student, Gustave Roussy*

## Keynote Presentation

10:20-10:50



### A Regulatory Science Journey to the First FDA Approved Microbiome-based Drug

Ken Blount

*VP Microbiome Research, Ferring Pharmaceuticals*

10:50-11:30

## Coffee Break

11:30-12:45



### Discovery & Preclinical

Chaired by François Leulier



11:30-11:55



### Developing a Rational Phage Therapy Treatment

Laurent Debarbieux

*Research Director, Institut Pasteur*

11:55-12:20



### Disentangling the Microbiome of Inflammatory Bowel Disease and the Role of Machine Learning

Marcus Claesson

*Associate Professor, Univeristy College Cork*

12:20-12:45



### Challenges, Efforts and Initiatives to Promote Microbiome-based Drug Discovery in Japan

Jun Terauchi

*Steering Committee Chair, Japan Microbiome Consortium  
CSO, Metagen Therapeutics Inc.*

12:45-12:55



### Lyon, a Dynamic Place for Microbiome R&D: the "Cynbiome" Research Network

Florent Gerbaud

*Lead Advisor, Healthcare and Life Sciences, ADERLY - Invest in Lyon*

12:55-14:00

## Lunch



14:00-14:20

**Contrasting Data-Driven and Microbiology Driven Approaches for Microbiome Hypothesis Creation**Patricia Lepage  
*Research director, Team leader, INRAE*

14:20-14:40

**Engineering a Complex Synthetic Microbial Community for Modulation of Bile Acids**Alice Cheng  
*Clinical Assistant Professor, Stanford University*

14:40-15:00

**Lessons From Synthetic Human Gut Communities**Karoline Faust  
*Associate Professor, KU Leuven*

15:00-15:20

**From Mice to Men - Which Models Should be Used for Pre-Clinical Validation of Microbiome Therapeutics?**Bärbel Stecher  
*Professor, LMU Munich*

15:20-15:40

**Engineering Defined Bacterial Consortia for Therapeutics Based on Trophic Interactions**Gabriel E. Leventhal  
*CSO, PharmaBiome AG*

15:40-16:00

**BMC128- A Rationally Designed LBP Consortium's Journey to the Clinic**Shiri Meshner  
*VP R&D, Biomica Ltd.***16:00-16:30 Panel Discussion: From Concept to Consortium**Patricia Lepage *Research Director, Team Leader, INRAE*  
Tomas de Wouters *Co-founder/CEO, PharmaBiome AG*  
Alice Cheng *Clinical Assistant Professor, Stanford University*  
Bärbel Stecher *Professor, LMU Munich*  
Noora Ottman *Head of Drug Substance Development, Bacthera***16:30-17:00 Coffee Break****17:00-18:00 SoHO Revision and its potential impact(s) on microbiome-based medicinal products**

Chaired by Jean-Paul Pirnay



17:00-17:25

**Presentation title TBD**Stefafaan van der Spiegel  
*Team Leader - Substances of Human Origin, European Commission*

17:25-17:50

**EDQM Standards in the SoHO Field**Mirela Bušić  
*Head of SoHO Standards Section, EDQM (CoE)***17:50-18:30 Panel Discussion: SoHO Revision and its Potential Impact(s) on Microbiome-Based Medicinal Products**

Moderated by Magali Cordaillat-Simmons



Overview by Céline Druart

Sarah Lebeer *Professor, University of Antwerp*  
Randi Rich *Head Of Operations, Executive Manager & Co-founder, Freya Biosciences*  
Bruno Pot *Science Director, Yakult Europe*  
Arnaud Beurdeley *Senior Regulatory Consultant/Senior Regulatory Consultant, Voisin Consulting Life Sciences (VCLS)*  
Jean-Paul Pirnay *Head of the Laboratory for Molecular and Cellular Technology (LabMCT), Queen Astrid Military Hospital*

08:15-08:55 **Welcome Coffee & Registrations**

08:55-09:00



**Conference Opening & Welcome Address Day 2**

Sandrine Claus

*President, Pharmabiotic Research Institute*

09:00-10:00



**Market**

Chaired by Georges Rawadi



09:00-09:20



**Microbiome Drug Development: What Does (Seem) to Work and What Does Not?**

Luis Gosálbez

*Managing Director, Sandwalk Bioventures*

09:20-09:40



**A Future Roadmap for Microbiome-Based Therapeutics and Well-Being Investment: Perspective and Strategy**

Chiaki Tsuboi

*Director, Corundum Systems Biology*

09:40-10:00



**Considerations for Spinning Out: Microbiome Technology Transfer**

Hervé Ansanay

*Biotech Alliance Manager in the Industrial Partnerships Department, Réseau SATT (SATT Network)*

10:00-10:30 **Panel Discussion: Translational Microbiome**



Georges Rawadi *Chief Biotech Studio, eureKARE/Board Member, Apmonia and Alia Therapeutics*

Hervé Ansanay *Biotech Alliance Manager, Réseau SATT (SATT Network)*

Heloise Breton *Senior Product Manager, Microbiome Devices and Services, DNA Genotek*

Alex van Belkum *CSO, BaseClear*

Nigel Titford *CEO, BioGaia Pharma AB*

Nick Mazzucca *Director of Business Development, Arranta Bio*

10:30-11:00 **Coffee Break**

11:00-12:40



**First In-Human Trials**

Chaired by Massimo Marzorati



11:00-11:25



**Gut Microbiota in Parkinson's Disease – From the Basics to the Clinic**

Filip Schepersjans

*Adjunct Professor of Neurology, Helsinki University Hospital/CEO, NeuroBiome Ltd.*

11:25-11:50



**Exploration of a Live Biotherapeutic Product With *lactobacilli* Against SARS-CoV-2 and Related Viruses**

Sarah Lebeer

*Research Professor, University of Antwerp*

11:50-12:15



**Pioneering a New Class of Microbial Immunotherapies for Women's Health**

Randi Rich *Head Of Operations, Executive Manager & Co-founder, Freya Biosciences*

Elleke Bosma *Director Microbiome Research, Freya Biosciences*

12:15-12:40



**Bloom Science and Biose Industrie - A Biotech and CDMOs Journey into the Clinic**

Christopher Reyes *CEO, Co-founder, Director, Bloom Science*

Claire Derlot *Head of Programs, Biose Industrie*

12:40-14:00 **Lunch**



## Late Stage Clinical Trials

Chaired by Sandrine Claus



14:00-14:20



### Live Biotherapeutic Products (LBPs) Filling Unmet Needs in Chronic Health Conditions

Wayne Finlayson  
*Chief Executive Officer, Servatus Ltd*

14:20-14:40



### Pharmaceutical Grade Probiotics – Navigating the Regulatory Roadmap to Achieve Clinical Success

Staffan Strömberg  
*CEO, Infant Bacterial Therapeutics*

14:40-15:00



### Regulatory Science Challenges Over the Life of a Microbiotic Medicinal Product: A Case History

Chiara Bertarello  
*Business Development & Contracts Management, Proge Farm*

15:00-15:20



### Developing Microbiome Ecosystem Therapies™ to Improve Patients' Survival in Oncology

Hervé Affagard  
*Chief Executive Officer, Maat Pharma*

15:20-15:40



### The Role of Lacidofil® in Gut Health and Beyond

Marie-Laure Oula  
*Clinical Program Manager, Lallemand Health Solutions*

15:40-16:15

## Coffee Break

16:15-17:45



## Innovation Showcase

Chaired by Warren Flood



### Engineering Safe and Effective Programmable Microbial Therapies

Ruben Vazquez Uribe  
*Co-principal Investigator, Novo Nordisk Foundation Center for Biosustainability*



### Developing Microbial Biotherapeutics for the Treatment of Breast Cancer

Christopher Price  
*Doctoral Researcher, Quadram Institute Biosciences*



### Bottom-Up Approach for the Identification of Probiotic Strains: The Example of Bactokind, a Bacterial Consortium With Clear Mechanism of Action for the Alleviation of Infant Colic

Vanesa Natalin Rocha Martin  
*CEO & Co-Founder, Suri Biotech*



### Mapping Microbial Interactions for Efficient Microbial Product Discovery

Cheri Ackerman  
*Cofounder & CEO, Concerto Biosciences*



### Opening the Black Box: Moving from Microbiome Understanding to Product Assessment

Matthew Tebeau  
*Chief Strategy & Partnering Officer, Proteon Pharmaceuticals*



### The Power of Zeus - A Fully Integrated Synthetic Biology Platform for Endolysin Discovery and Engineering

David Corcoran  
*Co-Founder and COO, CC Biotech Ltd.*



### Closing Address and Conference Close

Sandrine Claus  
*President, Pharmabiotic Research Institute*